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Abstract  
 
Background. Patients with schizophrenia (SZ) are a vulnerable, underserved and 
undertreated population which has been neglected in health disparities work. We have little 
understanding of the end of life (EOL) care in patients with a diagnosis of SZ and cancer. The 
objective of the study was to determine whether EOL care delivered to SZ patients with 
cancer (cases) differed from those delivered to patients without diagnosis of mental illness 
(controls). 
Methods. A population-based cohort study of all patients ≥15 years who died in hospital in 
France (2013-2016) and had a diagnosis of advanced cancer was undertaken (n=398,913). 
Within this cohort, cases and controls were selected and the following key outcomes were 
compared: access to palliative care and indicators of high-intensity EOL care. Multivariable 
generalized linear models were performed with adjustment for social deprivation, year of 
death, duration between cancer diagnosis and death, metastases, comorbidity and hospital 
category. 
Findings. The study included 2481 SZ patients and 222,477 controls. SZ patients were more 
likely to receive palliative care (adjusted Odds Ratio 1.61 [1.45;1.80], p<0.0001) and less 
high-intensity EOL care (e.g., chemotherapy 0.53 [0.46;0.62], p<0.0001; surgery 0.71 
[0.63,0.80], p<0.0001) than controls. The SZ patients were also more likely to die younger, 
had a shorter duration between cancer diagnosis and death, more thoracic cancers and 
comorbidities. 
Interpretation. The differences between SZ patients and controls suggest the existence of 
disparities in health and health care. These findings underscore the need for a better 
understanding of health inequalities to propose effective interventions in this vulnerable 
population. 
 
Keywords. High intensity end-of-life care, palliative care, cancer, schizophrenia, health 
services research.  
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Research in context 
 
Evidence before this study. Three databases (Medline, Web of Science and Google Scholar) 
were explored using the following paradigm based on the Mesh search words of Medline: 
“end-of-life” AND “cancer” AND “schizophrenia” between inception and March 2019. 
Previous works on end of life (EOL) in schizophrenia (SZ) patients with cancer are rare and 
reported contradictory findings. Few qualitative studies alerted on the risk of SZ patients for 
receiving poor quality EOL care, but their small sample sizes question the generalizability of 
findings. The only three quantitative studies on this issue are based on relatively dated data 
(before 2012 for the most recent study) with alternatively a lack of palliative care, similar or 
better EOL care and similar access to palliative care with more frequent invasive treatments 
but less chemotherapy and examinations. There are no recent quantitative studies exploring 
EOL care in SZ patients with cancer. Nationwide observational studies are necessary to 
provide objective and recent data on EOL care patients with SZ and then to provide a basis 
for improving their EOL. 
 
Added value of this study. This study was carried out on recent data at a national level with 
more than 200,000 death of cancer at hospital between 2013 and 2016. This study provided 
new data on EOL on a large population of patients with SZ and cancer (n=2481). Compared 
with the patients without diagnosis of mental illness, the SZ patients died 8 years earlier, had 
a higher level of comorbidities, more thoracic cancer, less metastases, a shorter duration 
from cancer diagnosis to death and more specialty center care. They were also less deprived. 
After matching and adjustment, they were found to have more palliative care and less high-
intensity EOL care.  
 
Implications of all the available evidence. Patients with SZ may benefit from a better EOL 
care (i.e., more palliative care and less high-intensity care) than their controls. The meaning 
of this finding may be discussed, resulting from either patients’ and families’ wishes or 
difficulties in offering early and relevant cancer care to SZ patients. Several striking 
characteristics of the SZ patients in this work (e.g., earlier age of death, higher level of 
comorbidities, shorter duration from cancer diagnosis to death) suggest the existence of 
disparities in health and health care. Caring for an individual with SZ and cancer requires 
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knowledge and expertise in both oncologic and psychiatric issues, and may call for better 
education training of health care professionals and care coordination/integration.  
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Introduction 
Cancer is a leading cause of death worldwide. With earlier detection of cancer and 
significant progress in treatments and supportive care in recent years, the survival and 
quality of life of cancer patients have improved greatly. However, not all cancer patients 
benefit equally from these advances. Racial minorities, low socio-economic status, lack of 
medical insurance, residence in remote areas, elderly age, and mental illnesses are all 
factors that may affect cancer treatment, survival, and care quality 1. Among mental 
illnesses, patients with schizophrenia (SZ) are one of the most vulnerable, underserved and 
undertreated population 2,3 which has been neglected in health disparities work and cancer 
health services research 4. SZ is associated with a marked decrease in life expectancy, 
approximately 14 years on average, essentially due to accidents, suicide and physical 
illnesses including cancer. Compared to patients without diagnosis of mental illness, SZ 
patients suffers from an increased delay in diagnoses and lower rates of adapted care due to 
both physician- (stigma, diagnostic overshadowing) 5,6 and patient- (insight into illness, help 
seeking) related factors, observations that are being reported around the world. SZ patients 
have been specifically reported to have a 1.5- to 4-fold higher cancer mortality 4,7–9 and 
lower rates of cancer screening exams 10. While most of the studies have focused on the 
debate over an increased or decreased risk of cancer incidence in SZ, only a few have 
explored end-of-life (EOL) care in patients with a diagnosis of SZ and cancer.  
Palliative care is an approach that improves the quality of life of patients and their 
families who are coping with problems associated with life-threatening illness 11. Such 
improvement is made through prevention, assessment, and treatment of pain and other 
symptoms and the provision of psychological, emotional, and spiritual support. Palliative 
care is patient and family centered and emphasizes patient autonomy and advance planning 
for care 12. Patients become eligible for palliative care delivered by a hospice organization at 
the point they are expected to have less than six months of remaining life. Cure of the 
terminal illness is no longer being pursued. Most previous works on EOL and cancer were 
performed in population without diagnosis of mental illness with two major concerns about 
poor-quality EOL care 12–15: (i) lack of referral or late referral to palliative care unit; (ii) high-
intensity EOL care (Hi-EOL) resulting in high rates of emergency department (ED) visits, 
intensive care unit (ICU) stays, overuse of chemotherapy and all potentially life-prolonging 
interventions near death. In addition to well-known barriers to optimal EOL care (e.g., 
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inadequate advance care planning, lack of communication between professionals and 
patients or their natural caregivers, poor health literacy, uncertainty about imminence of 
death) 14,16,17, some barriers may specifically affect patients with SZ such as stigma and 
common stereotypes regarding mental illnesses and the personal factors of the patients 
such as persecutory delusion and attribution bias, memory and attention impairments, 
avolia/lack of motivation, hostility, impaired autonomy, social withdrawal and increased 
isolation/poor social support in the end of life 3,5. EOL care is optimized when patients and 
their families participate in determining goals of care, yet half of SZ patients have 
impairments in decision-making capacity and when incapacitated, frequently lack surrogate 
decision makers 18.  
Previous works on EOL in SZ patients with cancer are rare and reported contradictory 
findings. Few qualitative studies alerted on the risk of SZ patients for receiving poor quality 
EOL care, but their small sample sizes question the generalizability of findings 19. The only 
three previous quantitative studies are based on relatively dated data (before 2012 for the 
most recent study) with alternatively a lack of palliative care 20, similar or better EOL care 18 
and similar access to palliative care with more frequent invasive treatments but less 
chemotherapy and examinations 21. There are no recent quantitative studies exploring EOL 
care in SZ patients with cancer. Nationwide observational studies are necessary to provide 
objective and recent data on EOL care patients with SZ and then to provide a basis for 
improving their EOL. 
 
The objective of this study was to determine whether the EOL care delivered to SZ 
patients with cancer differed from those delivered to patients without diagnosis of mental 
illness. 
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Methods 
Study design and data source 
This is a population-based cohort study of all patients aged ≥15 years who died from 
cancer in the hospital in France between January 1, 2013, and December 31, 2016. The study 
was based on the French national hospital database (Programme de Médicalisation des 
Systèmes d’Information (PMSI)), in which administrative and medical information is 
systematically collected for acute (PMSI-MCO) and psychiatric (PMSI-PSY) care. This 
information is anonymized and can be reused for research purposes 15. The PMSI is based on 
diagnosis-related groups, and all diagnoses are coded according to the International 
Classification of Diseases, Tenth Revision (ICD-10). The selection process, inclusion and 
exclusion criteria are presented in the Figure 1.  
From this selection, we defined 3 populations: 
1) Cases: The SZ patients were patients with a SZ diagnosis according to the specific ICD 
codes (F20*, F22*, F25*) in the PMSI-MCO database and/or in the PMSI–PSY database. 
2) Controls: The patients without diagnosis of mental illness were patients from the PMSI-
MCO database without psychiatric conditions according to the specific ICD codes 
(chapter F*) and without admission in psychiatry (PMSI–PSY). 
3) Matched controls: Cases and controls were matched using a 1:4 ratio according to 3 
criteria: age at death (+/- 2 years), sex and primary cancer localization (15 modalities). 
Outcome measures 
The different outcomes are based on previously defined criteria 12,17 and are presented 
in Table 1. 
Appendix Table A1 lists the specific codes used for each outcome. 
Collected data 
Six sociodemographic, clinical or hospital characteristics were collected due to their 
potential impact on the EOL care of patients.  
- Social deprivation assessed by an index validated on French data and based on the postal 
code of the domicile 22. The FDep09 index involves four socioeconomic ecological variables: 
percentage of high-school graduates, median household income, percentage of blue-collar 
workers and the unemployment rate. The FDep09 index was categorized according to 
quartiles, from the least (Q1) to the most deprived area (Q4). 
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- year of death (as the EOL practice may have evolved throughout time as mentioned in the 
rationale); 
- duration from cancer diagnosis to death; 
- comorbidities assessed using the Charlson modified Comorbidity Index 23 (computed from 
ICD-10 codes recorded as primary or secondary diagnoses over the course of the last 3 
months of life, excluding dementia and the 2 items referring to cancer, i.e., metastatic solid 
tumor and malignancy); 
- metastasis (ICD-10 codes C78 and C79) (as a metastasis diagnosis may accelerate palliative 
care admission); 
- hospital category (at last hospitalization before death). 
Statistical analysis 
The analyses were conducted in 2 steps. 
First, comparisons between cases and controls (unmatched populations) were 
performed for sociodemographic, clinical and hospital data: Chi-square tests or Student’s t 
tests according to the nature of the variable (step 1). 
Second, comparisons between cases and matched-controls were performed using 
univariate conditional logistic regressions for binary outcome measures and univariate 
generalized mixed models with log-normal distribution for quantitative outcomes. Then, we 
performed as many multivariate analyses as outcomes to analyze the association between 
the groups (cases/ matched-controls) and each outcome. Six confounding factors were 
included in the models: social deprivation (4 categories/quartiles from the most favored (Q1) 
to the most deprived area (Q4)), year of death (4 categories: 2013 to 2016), duration 
between cancer diagnosis and death (days), metastases (yes/no), Charlson modified 
comorbidity index (3 categories: 0, 1 or 2, >=3 comorbidities) and hospital category (2 
categories: specialty for cancer vs. nonspecialty centers). These analyses were performed 
with a multivariable generalized linear model  with the matched cluster as a random 
intercept using the PROC GLIMMIX in SAS (step 2). For quantitative data, the response 
distribution was lognormal and the identify link function was used. For binary data, the 
response distribution was binomial and the logit link function was used. To assess goodness-
of-fit of the models, we reported the ratio between the Pearson Chi-square statistic and its 
degrees of freedom. Multiple comparison corrections (false discovery rate) were performed. 
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The statistical analysis was performed with SAS 9.4 (SAS Institute). Statistical significance 
was defined as p<0.05.  
 
Role of the funding source 
This work was funded by AP-HM (Assistance Publique des Hôpitaux de Marseille) and 
Aix-Marseille University. The funder of the study had no role in study design, data collection, 
data analysis, data interpretation, or writing of the report. The corresponding author had full 
access to all of the data and the final responsibility to submit for publication. 
 
Results 
Overall, 3,361,043 patients with cancer were identified in France between 2013 and 
2016. Among them, 398,913 deaths (11.9%) were identified during this period, and 224,958 
(6.7%) were finally included in this study after removing dementia and psychiatric diagnoses 
other than schizophrenia (Flow chart Figure 1). A total of 2481 patients were defined as SZ 
patients (cases) and compared to 222,477 patients without diagnosis of mental illness 
(controls) (step 1). A total of 2,474 SZ patients were then matched with their 9,896 controls 
(7 SZ patients were excluded in the matching process due to the absence of matched 
controls) (step 2). 
 
1) Comparison between cases and controls 
Compared to controls, SZ patients were found (Table 2): 
- to die younger and to be less deprived. No statistically significant difference was found 
with respect to sex; 
- to have a shorter duration from cancer diagnosis to death; 
- to have more thoracic, central nervous system, respiratory system and less digestive and 
male genitalia cancers; 
- to have a more frequent comorbidities, including more peripheral vascular disease, 
hemiplegia or paraplegia, mild liver disease, HIV/AIDS, chronic pulmonary disease  and 
less congestive heart failure; 
- to have more specialty center care for the last hospitalization. 
 
 10 
2) Comparison between cases and matched controls 
In addition to the abovementioned differences, SZ patients were found to have lower 
metastases than their matched controls in the univariate analyses (Table 3). 
In the multivariate analysis, SZ patients were found (Table 4) 
- to have more frequent palliative care unit admissions in the last 31 days of life and in the 
last 3 days of life  and a longer length of palliative care follow-up before death;  
- to have less chemotherapy, surgery, imaging, endoscopy and blood transfusion ; 
- to be less likely to be admitted to an air extraction chamber, to an acute care unit with 
longer LOS and to have fewer deaths in the ICU/ED. 
All the Pearson Chi-Square/DF values were lower than 1, except for the duration 
between cancer diagnosis and death which was greater than 1 but in an acceptable range 
(1.47). Appendix Table A2 lists the Pearson Chi-Square/DF values for each model. 
 
Discussion 
The present findings may be summarized as follows: between 2013 and 2016, 2481 
patients with SZ and cancer died in French hospital care. Compared with patients without 
diagnosis of mental illness, the SZ patients died 8 years earlier, had a higher level of 
comorbidities, more thoracic cancer, less metastases, a shorter duration from cancer 
diagnosis to death and more specialty center care. They were also less deprived. After 
matching and adjustment, they were found to have more palliative care and less Hi-EOL 
care. 
 
Our study cannot determine with certainty why there is a discrepancy in EOL 
outcomes for SZ vs. control patients. However, as described in recent works 3, the 
differences found in our work between SZ patients and controls suggest the existence of 
disparities in health and health care.  
SZ patients were found to die 8 years younger from cancer than controls, which is 
consistent with higher level of comorbidities found in the present results and in previous 
studies suggesting a reduced life expectancy in SZ patients due to somatic causes and 
comorbidities 24. These frequent and multiple somatic comorbidities may negatively 
influence the prognosis of cancer: modifications and complexity of cancer treatment, the 
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necessity of close collaboration with primary care providers which may be insufficient in 
advanced psychiatric disease, and poorer survival. Models of integrated care for people with 
severe mental disorders and somatic comorbidities should be further developed in France, 
before cancer occurrence and during cancer care. 
In our study, SZ patients died more frequently of tobacco-related cancers, whereas 
schizophrenia was not associated with an increased risk of lung cancer incidence in the 
general population 25. This suggests that tobacco-related cancers may be more lethal in this 
specific population, which had been already found in a previous French cohort study in the 
1990s 8. SZ patients may have delayed cancer diagnosis and may present with a more severe 
form of cancer 4, as suggested by the shorter duration from cancer diagnosis to death. 
Barriers to lung cancer care has been also reported for SZ patients 4. SZ has been extensively 
associated with high rates of hard tobacco smoking. Thirty-percent of the French general 
population is currently identified as engaging in daily tobacco smoking vs. 52% of SZ 
outpatients who have high rates of severe nicotine dependence 26; furthermore, more than 
two-thirds of excess deaths due to natural causes in SZ patients are due to smoking-related 
diseases 27. A higher lifetime tobacco smoking dose-effect as well as failing to quit smoking 
after a cancer diagnosis may increase thoracic cancer mortality in this population. Smoking 
cessation programs and cancer screening should be reinforced to prevent thoracic cancer 
and to improve cancer prognosis.  
SZ patients were found to have lower rates of metastases compared to their matched 
controls, suggesting a difference in cancer stages at first contact with oncology team. An 
early identification of cancers in SZ patients seems unlikely in light of our experience and the 
literature 28. More likely, patients may benefit less from complementary explorations than 
the controls, as suggested by their lower rates of imaging exams in the last month of life. 
Another hypothesis may be that SZ patients may be more likely to die from their primary 
local cancer before the development of metastases due to a lack or delayed treatment 
initiation. If this hypothesis was confirmed, a better cancer screening for SZ patients based 
on specific and targeted approaches is necessary. 
Patients with SZ were preferentially found in specialized centers, suggesting a lack of 
contact with secondary (i.e., non-specialty centers) and primary care (i.e., family physician) 
previously described in France 29. 
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Unexpectedly, patients with SZ were less deprived than controls while severe mental 
disorders have been extensively associated with low socio-economic level. Deprived patients 
with SZ may be more prone to die earlier from other causes of mortality including 
cardiovascular diseases, addictions and unnatural causes of deaths (including trauma and 
self-attempt). Social deprived SZ patients who die from cancer may also have a lower access 
to EOL care compared to the most favored ones. A lack of social support in the elderly with 
SZ (e.g., due to parents’ aging and divorce) may be more pronounced in deprived 
populations, leading to a rupture with the healthcare system, lack of cancer diagnosis and 
cancer care, adherence issues and lost to follow-up/deaths outside the hospital 30.  
 
SZ patients did not benefit from the same care as their matched controls in our study. 
SZ patients had more palliative care, which was not expected according to the results of 
previous studies 18–21. This result appears to be coherent with the lesser amount of high-
intensity care provided to SZ patients: less chemotherapy, surgery, imaging, endoscopy, 
fewer blood transfusions. Less chemotherapy and imaging were previously reported in a 
study based on the Taiwanese national database 21. In contrast, this same study found that 
more surgery was performed in SZ patients than in patients without diagnosis of mental 
illness 21. Three levels of explanations can be proposed 4.  
On the provider level, treating physicians may be more prone to switch to palliative 
care in patients with severe mental illness, given that providing treatments with a high risk 
of toxicity and with strict administration protocols may be more difficult in patients with 
lower treatment adherence and cognitive impairment. This explanation may also be a 
reason for the lower rates of chemotherapy in our sample. SZ patients also appear to 
experience a higher rate of postoperative complications, including respiratory failure, sepsis, 
deep venous thrombosis, pulmonary embolism, paralytic ileus, stroke, and postoperative 
delirium 31, which may explain the lower rate of surgery considering the unfavorable benefit-
risk balance. SZ Individuals may be excluded from making decisions about their EOL care in 
part due to provider concerns about their emotional fragility and competence 32. These 
results may also reflect mental illness stigma and diagnostic overshadowing (i.e., inadequate 
or delayed treatment on account of the misattribution of their physical symptoms to their 
mental illness) described in previous works 5,6.  
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On the patient level, the lower rates of high-intensity care may be due to SZ patients’ 
hostility toward treatment, which may be associated with a higher risk of violence 
(hostility/paranoid delusion, psychomotor agitation) 4. A previous study has also found that 
SZ patients may more frequently document do not resuscitate orders than patients without 
diagnosis of mental illness 18.  
On the health system level, palliative care units have been designed to manage 
complicated situations (including lack of social support/isolation, homelessness and 
impaired autonomy that may interfere with each step of cancer care) 4,33, which may explain 
the longer length of follow-up in SZ patients in palliative care units in our study.  
 
Limitations. These results should be taken with caution as only deaths were analyzed 
in the present study. Another study should determine the cancer mortality rates in SZ 
patients compared to matched controls and should explore the whole cancer care of SZ 
patients. Data on psychiatric symptomatology and psychotropic drugs were not available in 
the database and have not been explored. Our work only describes advanced cancer 
patients who died in hospitals, which may restrict the generalizability of our findings to less 
advanced cancer and patients who died at home. However, only 3% of patients died at home 
and 13% died in nursing homes in 2013 in France 34. It should be mentioned that people 
receiving hospital palliative care died more frequently in the hospital compared to people 
not receiving such care; however, our patients were matched to their controls according to 
their age at death, sex and primary cancer localization, and the results were adjusted for 
social deprivation, year of death, duration between cancer diagnosis and death, metastases, 
Charlson modified comorbidity index and hospital category, which strengthens our results. 
Strengths. The strength of this study is the analysis of a 4-year national database of 
more than 200,000 deaths from cancer in France. It is the largest epidemiological study 
performed in the field of EOL in SZ patients to date. We used a dedicated method of patient 
selection, which has been validated by the French National Institute for Cancer (INCA).  
 
Conclusion 
Patients with SZ may benefit from a better EOL care (i.e., more palliative care and less high-
intensity care) than their controls. The meaning of this finding may be discussed, resulting 
from either patients’ and families’ wishes or difficulties in offering early and relevant cancer 
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care to SZ patients that may lead providers to orientate them more quickly toward palliative 
care units. Several striking characteristics of the SZ patients raise questions about their 
quality of care. Caring for an individual with SZ and cancer requires knowledge and expertise 
in both oncologic and psychiatric issues, and may call for better education training of health 
care professionals and care coordination/integration. These findings underscore the need 
for a better understanding of health inequalities to propose effective interventions in this 
vulnerable population. 
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